SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
478 37 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Subject 11419

Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform.

Cancer and Pain Products
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
478What was a base (May15 to May31) for +3M share short increase? What changed (negMiljenko Zuanic-June 13
477Enrolment rate and centers opening rate for melanoma P3 still *confuse* all whatMiljenko Zuanic-June 4
476Shares are up nearly $3.00 per share in pre-market, so Wall Street must like thArthur Radley-June 3
475214 at ASCO-2019 nektar.comMiljenko Zuanic-June 1
474Regorafenib for osteosarcoma: ascopubs.orgMiljenko Zuanic-May 30
473That was my point/concern. And Mary mentioned on cc, only FEW more subjects to Miljenko Zuanic-May 16
472Unless the sarcoma-IST data to be presented at ASCO are much, much better than tDewDiligence_on_SI-May 16
471So much about accelerated approval,......... why they even mentioned at cc????Miljenko Zuanic-May 16
470That trial, two centers (second is Anderson), was on my screen from day one. IncMiljenko Zuanic-May 9
469They certainly devoted a lot of time to the sarcoma IST conducted by Dr. D'ADewDiligence_on_SI-May 9
468Very informative 1Q cc: finance.yahoo.comMiljenko Zuanic-May 9
467twitter.comMiljenko Zuanic-March 2
466Cetus was swallowed by Chiron (which develop Proleukin), which was bought by NovMiljenko Zuanic-February 26
465Whatever happened to Cetus and Chiron IL-2? Are they still relevant?semi_infinite -February 26
464Competitor: fiercebiotech.comMiljenko Zuanic-February 26
463Yes, it looks that way. Time-passed is too short to have many new updates (numbeMiljenko Zuanic-February 26
462I don't know why they are having a call if its not substantially more of an ghmm-February 26
461How long will they talk now, slicing 10 subjects from P1-escalation phase (this Miljenko Zuanic-February 25
460<BMY and NKTR agree, evidently.> With not so strong conviction...only sinMiljenko Zuanic-February 11
459BMY and NKTR agree, evidently.DewDiligence_on_SI-February 11
458ASCO-GU meetinglibrary.asco.org <22 pts had available baseline PD-L1 resultsMiljenko Zuanic-February 11
457Than again, he is/was strong seller from 2014! finviz.comMiljenko Zuanic-January 30
456Nicholson J. sold without any *reserve* for taxes. Well, he can sell from main hMiljenko Zuanic-January 30
455Oppenheimer join club with 10% stake: secfilings.nasdaq.comMiljenko Zuanic-January 19
454Neoleukin...... endpts.comscaram(o)uche-January 11
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):